The binding of antigen to receptors on B lymphocytes transmits a signal to the lymphocyte. This signal along with factors from T cells and accessory cells results in differentiation of the cell to a plasma cell secreting specific antibody. Indirect evidence suggests that the signal associated with binding of antigen and other factors is transmitted by changes in the plasma membrane and intracellular messenger. However, studies of intracellular events associated with antigen induced B cell triggering or antigen specific tolerance thus far have utilized indirect methods. Direct measurement of intracellular changes was impossible due to the small proportion of specific antigen-binding lymphocytes in most lymphocyte preparations. The principal investigator has developed long term cultures of two normal murine B cell lines which are specific to the hapten dinitrophenyl (DNP). Under the appropriate conditions, the binding of antigen (DNP-Ficoll) or tolerogen (DNP-Murine IgG) to the B cell surface receptor specific for DNP results in either antigen driven B cell differentiation or tolerance induction, respectively. This is a proposal to study the intracellular changes which occur with the binding of the hapten to the receptor on two B cell lines, and to compare the changes which occur when the antigenic and tolerance-inducing forms of the hapten are used. We intend to determine changes in intracellular levels of cylic AMP, cyclic GMP, Ca2+ and cyclic AMP-dependent protein kinases, and profiles of intracellular protein phosphorylation. We will also examine phospholipid methylation and phospholipid phosphorylation in the lymphocyte plasma membrane during induction of B cell differentiation and tolerance. Thus, we will more precisely define the biochemical events associated with hapten-receptor binding which eventually lead to B lymphocyte triggering or tolerance.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI021066-02
Application #
3130979
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1984-04-01
Project End
1987-03-31
Budget Start
1985-04-01
Budget End
1986-03-31
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Aldo-Benson, M; Kluve-Beckerman, B; Hardwick, J et al. (1992) Ethanol inhibits production of messenger ribonucleic acid for kappa-chain in stimulated B lymphocytes. J Lab Clin Med 119:32-7
Aldo-Benson, M; Borel, H; Scheiderer-Pratt, L et al. (1989) Immunologic tolerance to DNA in B cell lines from both normal and autoimmune mice. Immunol Res 8:263-70
Aldo-Benson, M; Brooks, M S; Scheiderer-Pratt, L (1989) B cell hyperactivity in autoimmune continuous B cell lines. Immunol Res 8:271-80
Aldo-Benson, M (1989) Investigations of intrinsic abnormalities in DNA-specific B lymphocytes from autoimmune mice. J Autoimmun 2:269-82
Borel, Y; Borel, H (1988) Oligonucleotide linked to human gammaglobulin specifically diminishes anti-DNA antibody formation in cultured lymphoid cells from patients with systemic lupus erythematosus. J Clin Invest 82:1901-7
Aldo-Benson, M; Tsao, B P (1987) The role of cytoplasmic free calcium concentration in B-cell tolerance. Cell Immunol 108:335-42
Aldo-Benson, M A (1986) An in vitro model for clonal anergy in continuously growing antigen-specific B-cell lines. Cell Immunol 101:391-402
Partain, K; Jensen, K; Aldo-Benson, M (1986) Inositol phospholipid and intracellular calcium metabolism in B lymphocytes stimulated with antigen. Biochem Biophys Res Commun 140:1079-85
Aldo-Benson, M; Scheiderer, L; Dwulet, F E (1986) 2,4-Dinitrophenyl (DNP)-specific continuous B cell lines as a model system for studying B cell activation and tolerance. Eur J Immunol 16:69-74
Brooks, M S; Aldo-Benson, M (1986) Defects in antigen-specific immune tolerance in continuous B cell lines from autoimmune mice. J Clin Invest 78:784-9

Showing the most recent 10 out of 13 publications